Metastatic liver cancer is a condition in which mutated cells in the liver have developed and spread to other organs in the body. At this stage, treatment is quite difficult and the patient's survival time is relatively short.

Digital subtraction angiography and radioactive drug injection for liver cancer treatment is a modern treatment method, minimally invasive intervention, so it rarely causes serious complications for patients, and the hospital stay is short. However, to perform this technique, experienced doctors and hospitals with vascular intervention centers are required.

Digital subtraction angiography and portal vein embolization are methods of treating primary liver cancer when the patient is indicated for major liver resection but the remaining liver volume is insufficient and there is no liver failure.

Liver cancer is the most common cancer in both men and women. Early diagnosis is important for effective treatment. Diagnostic methods for liver cancer include blood tests and imaging studies.

Liver cancer with leg edema, abdominal distension, and blood in the stool are common symptoms that need to be examined and treated. Find out information about this phenomenon with Vinmec through the article below.

Pain in liver cancer is very common. In addition to questions such as does liver cancer hurt, or does terminal liver cancer hurt, most patients are also very interested in effective ways to relieve pain.

Liver cancer is curable and how long patients live depends on when the disease is detected. If detected early, treatment effectiveness can be as high as 80%.

Liver cancer is a common disease in both sexes. The disease progresses quite silently in its early stages, so patients often miss the best opportunity for treatment. Therefore, the possibility of cure and survival time of liver cancer patients is not high.

In liver cancer, portal vein thrombosis is common. Many studies have shown that portal vein thrombosis is associated with the development of metastatic masses in liver cancer, and increases the risk of early recurrence after treatment.